4.7 Article

Alzheimer's disease multiclass diagnosis via multimodal neuroimaging embedding feature selection and fusion

期刊

INFORMATION FUSION
卷 66, 期 -, 页码 170-183

出版社

ELSEVIER
DOI: 10.1016/j.inffus.2020.09.002

关键词

Alzheimer's disease; Multimodal neuroimaging; Multiple kernel learning; Feature selection; Neuroimaging biomarker; Multiclass classification; Multimodal fusion

资金

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI), USA (National Institutes of Health) [U01 AG024904]
  2. DOD ADNI, USA (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica, Inc.
  10. Biogen
  11. Bristol-Myers Squibb Company
  12. CereSpir, Inc.
  13. Cogstate
  14. Eisai Inc.
  15. Elan Pharmaceuticals, Inc.
  16. Eli Lilly and Company
  17. EuroImmun
  18. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd.
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  23. Johnson & Johnson Pharmaceutical Research & Development LLC.
  24. Lumosity
  25. Lundbeck
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC.
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corporation
  31. Pfizer Inc.
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Company
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research

向作者/读者索取更多资源

The study introduces a novel multiclass classification framework for AD based on multimodal neuroimaging with embedded feature selection and fusion. By using regularization and optimization techniques, it achieves feature selection and fusion, proving the convergence of the optimization process. Experimental results demonstrate the method's promising performance.
Alzheimer's disease (AD) will become a global burden in the coming decades according to the latest statistical survey. How to effectively detect AD or MCI (mild cognitive impairment) using reliable biomarkers and robust machine learning methods has become a challenging problem. In this study, we propose a novel AD multiclass classification framework with embedding feature selection and fusion based on multimodal neuroimaging. The framework has three novel aspects: (1) An l(2,1)-norm regularization term combined with the multiclass hinge loss is used to naturally select features across all the classes in each modality. (2) To fuse the complementary information contained in each modality, an l(p)-norm (1 < p < infinity) regularization term is introduced to combine different kernels to perform multiple kernel learning to avoid a sparse kernel coefficient distribution, thereby effectively exploiting complementary modalities. (3) A theorem that transforms the multiclass hinge loss minimization problem using the l(2,1)-norm and l(p)-norm regularizations to a previous solvable optimization problem and its proof are given. Additionally, it is theoretically proved that the optimization process converges to the global optimum. Extensive comparison experiments and analysis support the promising performance of the proposed method.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据